|
Ivanova E.S.
Phosphaside and lamivudine as a nucleoside base of first-line antiretroviral therapy regimens for HIV infection
|
№4 / 2016
|
|
Podymova A.S.
Results of examination of pregnant women’s sexual partners for HIV infection: The experience of the Sverdlovsk Region
|
№4 / 2016
|
|
Kanestri V.G., Yagodkin М.V.
Use of non-boosted atazanavir in clinical practice
|
№2 / 2016
|
|
Sizova N.V., Volova L.Yu., Malyuzhenko I.V., Isaeva G.N., Koveleno A.Yu., Minaeva S.V., Topolskaya S.V., Voronin E.E., Okhonskaya L.V.
The first results of using the combined drug rilpivirine/tenofovir/emtricitabine in Russian patients with HIV infection in real clinical practice
|
№6 / 2015
|
|
Kravchenko A.V., Kanestri V.G.
HIV drug resistance: Dolutegravir is a second-generation HIV integrase inhibitor
|
№6 / 2015
|
|
Kozyrina N.V., Yurin O.G.
A virologic response as a hallmark of excellence: TDF/FTC or TDF/3TC
|
№6 / 2015
|
|
Kravchenko A.V., Orlova-Morozova E.A., Shimonova T.E., Kozyrev O.A., Nagimova F.I., Bychko V.V., Vostokova N.V., Zozulya O.V.
The efficacy and safety of a new Russian HIV non-nucleoside reverse transcriptase inhibitor (VM-1500, Elpivirine) as a component in an antiretroviral therapy regimen
|
№5 / 2015
|
|
Kravchenko A.V.
Antiretroviral therapy regimens containing the HIV protease inhibitor saquinavir
|
№3 / 2015
|
|
Kravchenko A.V., Kanestri V.G., Gankina N.Yu.
Efficacy and safety of antiretroviral therapy regimens containing etravirine for HIV-infected patients
|
№2 / 2015
|
|
Kanestri V.G., Kravchenko A.V., Gankina N.Yu.
Hepatotoxicity of antiretroviral therapy in HIV-infected patients
|
№1 / 2015
|
|
Yurin O.G., Kravchenko A.V., Kanestri V.G., Pokrovskaya A.V., Shakhgildyan V.I., Volkova S.B.
Dual antiretroviral therapy with lopinavir and ritonavir
|
№6 / 2014
|
|
Kozyrina N.V., Narsia R.S., Yurin O.G.
Abacavir and lamivudine as a nucleoside base of antiretroviral therapy
|
№5 / 2014
|
Русский
